Trial NCT04588480
Publication Haranaka M, Nat. Commun., 2021
Primary outcome on the report: 1) local reactions or 2) systemic events for 7 days after each dose; 3) adverse events from dose 1 through 1 month after dose 2; 4) serious AEs (SAEs) collected from dose 1 through 12 months after dose 2 (reported to 1 month after dose 2 in this report); 5) hematology and clinical chemistry laboratory parameters up to 7 days after dose 2; 6) geometric mean titers (GMTs) of SARS-CoV-2 neutralization 1 month after dose 2; 7) geometric mean fold rises (GMFRs) of neutralizing titers from baseline to 1 month after dose 2.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.